"We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US," said Lars Fruergaard Jorgensen, Novo Nordisk CEO.
The U.S. cannabis industry has grown significantly, projected to surpass $50 billion in sales, yet faces numerous challenges due to regulatory, banking, and competitive pressures.